Publications by authors named "Clayton D Harro"

Claim this Profile
I
Interrogation of a live-attenuated enterotoxigenic vaccine highlights features unique to wild-type infection.
Subhra Chakraborty, Arlo Randall, Tim J Vickers, Doug Molina, Clayton D Harro

NPJ Vaccines· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severity.
Pardeep Kumar, F Matthew Kuhlmann, Subhra Chakraborty, A Louis Bourgeois, Jennifer Foulke-Abel, Clayton D Harro

J Clin Invest· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Experimental Challenge With Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine Development.
Subhra Chakraborty, Arlo Randall, Tim J Vickers, Doug Molina, Clayton D Harro

J Infect Dis· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severity.
Pardeep Kumar, F Matthew Kuhlmann, Subhra Chakraborty, A Louis Bourgeois, Jennifer Foulke-Abel, Clayton D Harro

J Clin Invest· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia coli Infection in Humans.
William E Yang, Sunil Suchindran, Bradly P Nicholson, Micah T McClain, Thomas Burke, Clayton D Harro

J Infect Dis· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.
Sharon E Frey, Laurence Peiperl, M Juliana McElrath, Spyros Kalams, Paul A Goepfert, Clayton D Harro

Clin Vaccine Immunol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.
Michael J Darsley, Subhra Chakraborty, Barbara DeNearing, David A Sack, Andrea Feller, Clayton D Harro

Clin Vaccine Immunol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies.
Clayton D Harro, Robert F Betts, Jonathan S Hartzel, Matthew T Onorato, Joy Lipka

Vaccine· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Norovirus vaccine against experimental human Norwalk Virus illness.
Robert L Atmar, David I Bernstein, Clayton D Harro, Mohamed S Al-Ibrahim, Wilbur H Chen

N Engl J Med· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.
Clayton D Harro, Michael N Robertson, Michelle A Lally, Lori D O'Neill, Srilatha Edupuganti

AIDS Res Hum Retroviruses· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.
Nina D Russell, Barney S Graham, Michael C Keefer, M Juliana McElrath, Steve G Self, Clayton D Harro

J Acquir Immune Defic Syndr· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Ligia A Pinto, Raphael Viscidi, Clayton D Harro, Troy J Kemp, Alfonso J García-Piñeres

Virology· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.
Ligia A Pinto, Philip E Castle, Richard B Roden, Clayton D Harro, Douglas R Lowy

Vaccine· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
Neil M Flynn, Donald N Forthal, Clayton D Harro, Franklyn N Judson, Kenneth H Mayer

J Infect Dis· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial.
Clayton D Harro, Franklyn N Judson, Geoffrey J Gorse, Kenneth H Mayer, Jay R Kostman

J Acquir Immune Defic Syndr· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Ligia A Pinto, Jessica Edwards, Philip E Castle, Clayton D Harro, Douglas R Lowy

J Infect Dis· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response.
Myong-Jin Kim, Anne N Nafziger, Clayton D Harro, Harry L Keyserling, Keith M Ramsey

Vaccine· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis